panobinostat
Selected indexed studies
- Panobinostat: first global approval. (Drugs, 2015) [PMID:25837990]
- Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. (Clin Lymphoma Myeloma Leuk, 2021) [PMID:34340951]
- Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a. (Cell, 2024) [PMID:38367616]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Panobinostat: first global approval. (2015) pubmed
- Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. (2021) pubmed
- Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a. (2024) pubmed
- Panobinostat for the management of multiple myeloma. (2017) pubmed
- Panobinostat for the Treatment of Multiple Myeloma. (2015) pubmed
- Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat. (2018) pubmed
- Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma. (2016) pubmed
- Panobinostat for the treatment of acute myelogenous leukemia. (2016) pubmed
- A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma. (2024) pubmed
- Panobinostat in lymphoid and myeloid malignancies. (2013) pubmed